United Therapeutics Corpo... (UTHR)
United Therapeutics Statistics
Share Statistics
United Therapeutics has 44.91M shares outstanding. The number of shares has increased by 1.23% in one year.
| Shares Outstanding | 44.91M |
| Shares Change (YoY) | 1.23% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 44.09M |
| Failed to Deliver (FTD) Shares | 587 |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 1.98M, so 4.42% of the outstanding shares have been sold short.
| Short Interest | 1.98M |
| Short % of Shares Out | 4.42% |
| Short % of Float | 4.51% |
| Short Ratio (days to cover) | 6.36 |
Valuation Ratios
The PE ratio is 13.34 and the forward PE ratio is 12.6. United Therapeutics's PEG ratio is 0.52.
| PE Ratio | 13.34 |
| Forward PE | 12.6 |
| PS Ratio | 5.54 |
| Forward PS | 3.2 |
| PB Ratio | 2.47 |
| P/FCF Ratio | 14.76 |
| PEG Ratio | 0.52 |
Enterprise Valuation
United Therapeutics Corporation has an Enterprise Value (EV) of 9.78B.
| EV / Earnings | 8.19 |
| EV / Sales | 3.4 |
| EV / EBITDA | 5.91 |
| EV / EBIT | 7.1 |
| EV / FCF | 9.05 |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.05.
| Current Ratio | 5.25 |
| Quick Ratio | 5.03 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.45 |
| Cash Flow / Debt | 4.42 |
| Interest Coverage | 32.1 |
Financial Efficiency
Return on equity (ROE) is 0.19% and return on capital (ROIC) is 15.86%.
| Return on Equity (ROE) | 0.19% |
| Return on Assets (ROA) | 0.16% |
| Return on Capital (ROIC) | 15.86% |
| Revenue Per Employee | $2,204,904.21 |
| Profits Per Employee | $915,785.44 |
| Employee Count | 1,305 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | 343.9M |
| Effective Tax Rate | 0.22 |
Stock Price Statistics
The stock price has increased by 35.02% in the last 52 weeks. The beta is 0.64, so United Therapeutics's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | 35.02% |
| 50-Day Moving Average | 338.81 |
| 200-Day Moving Average | 346.92 |
| Relative Strength Index (RSI) | 40.17 |
| Average Volume (20 Days) | 451.22K |
Income Statement
In the last 12 months, United Therapeutics had revenue of 2.88B and earned 1.2B in profits. Earnings per share was 26.44.
| Revenue | 2.88B |
| Gross Profit | 2.57B |
| Operating Income | 1.38B |
| Net Income | 1.2B |
| EBITDA | 1.65B |
| EBIT | 1.38B |
| Earnings Per Share (EPS) | 26.44 |
Balance Sheet
The company has 1.7B in cash and 300M in debt, giving a net cash position of 1.4B.
| Cash & Cash Equivalents | 1.7B |
| Total Debt | 300M |
| Net Cash | 1.4B |
| Retained Earnings | 7.22B |
| Total Assets | 7.36B |
| Working Capital | 3.14B |
Cash Flow
In the last 12 months, operating cash flow was 1.33B and capital expenditures -246.5M, giving a free cash flow of 1.08B.
| Operating Cash Flow | 1.33B |
| Capital Expenditures | -246.5M |
| Free Cash Flow | 1.08B |
| FCF Per Share | 23.91 |
Margins
Gross margin is 89.24%, with operating and profit margins of 47.86% and 41.53%.
| Gross Margin | 89.24% |
| Operating Margin | 47.86% |
| Pretax Margin | 53.49% |
| Profit Margin | 41.53% |
| EBITDA Margin | 57.5% |
| EBIT Margin | 47.86% |
| FCF Margin | 37.55% |
Dividends & Yields
UTHR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 8.58% |
| FCF Yield | 7.81% |
Analyst Forecast
The average price target for UTHR is $380, which is 23.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $380 |
| Price Target Difference | 23.3% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Stock Splits
The last stock split was on Sep 23, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 23, 2009 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 11.98 |
| Piotroski F-Score | 9 |